泽姆沃克斯
ZYME
25.03
-0.72
-2.80%
泽姆沃克斯
US · ZYME
#2828 按市值排名
上市于 2017
25.03
-0.72
-2.80%
实时 - 追踪5344个代码 - 心跳于413秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 98.15% -0.09pp
- 机构数量
- 252 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund52.96%
Mutual Fund31.90%
VC/PE Fund7.51%
Public Company4.83%
Individual/Insider1.32%
Private Company0.52%
Government Pension Fund0.43%
Other0.53%
主要股东 截至 2026-06-30
EcoR1 Capital, LLC
32.37% · 22.97M 股
Rubric Capital Management LP
9.86% · 7.00M 股
BlackRock
5.99% · 4.25M 股
Perceptive Advisors LLC
5.89% · 4.18M 股
BVF Partners L.P.
5.14% · 3.65M 股
Morgan Stanley
3.03% · 2.15M 股
Vanguard Capital Management, LLC
2.31% · 1.64M 股
BNPP Asset Management Holding
2.30% · 1.63M 股
Assenagon Asset Management S.A.
1.76% · 1.25M 股
Nextech Invest Ltd.
1.57% · 1.11M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 3次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| EcoR1 Capital, LLC | -- | 32.37% |
| Gregory Ciongoli | Director | 0.70% |
| Kenneth Galbraith | Chairperson & CEO | 0.32% |
| Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | 0.19% |
| Paul Moore | Chief Scientific Officer | 0.07% |
| Jeffrey T. Smith | -- | 0.04% |
| Troy Cox | Independent Director | 0.01% |
| Leone Patterson | CFO, EVP & Chief Business Officer | 0.00% |
| Brian Cherry | Director | -- |
| Nancy Davidson | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-05 | Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | Other Acquisition | +939 | $22.22 |
| 2026-05-12 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +119,000 | -- |
| 2026-05-12 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +178,000 | $24.57 |
| 2026-05-12 | Paul Schneider | Executive Vice President | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Other Derivative Acquisition | +47,000 | -- |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Other Derivative Acquisition | +70,000 | $27.35 |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Other Derivative Acquisition | +76,000 | -- |
| 2026-04-08 | Adam Schayowitz | Acting Chief Development Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-08 | Scott Platshon | Director | Other Derivative Acquisition | +47,000 | -- |
| 2026-04-08 | Scott Platshon | Director | Other Derivative Acquisition | +70,000 | $27.35 |
| 2026-04-08 | Scott Platshon | Director | Other Derivative Acquisition | +76,000 | -- |
| 2026-04-08 | Scott Platshon | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-05 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +169,000 | -- |
| 2026-04-05 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +178,000 | $25.84 |
| 2026-03-31 | Kristin Stafford | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-01-31 | Sabeen Mekan | Senior Vice President of Clinical Development | Initial Statement of Beneficial | 0 | -- |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Derivative Exercise and Sale | -30,424 | $22.67 |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +144,000 | -- |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +216,000 | $23.16 |
| 2026-01-11 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +222,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
泽姆沃克斯 讨论区 0 条评论